1072951-54-2 Usage
Description
2,6-Dichloropyridine-4-boronic acid is an organic compound with the molecular formula C5H4BCl2NO2. It is a derivative of pyridine, a heterocyclic compound with a nitrogen atom in the ring structure. The presence of two chlorine atoms at the 2nd and 6th positions, along with a boronic acid group at the 4th position, gives this compound unique chemical properties and reactivity.
Uses
Used in Pharmaceutical Industry:
2,6-Dichloropyridine-4-boronic acid is used as a key intermediate in the synthesis of various pharmaceutical compounds. Its unique chemical structure allows it to be a versatile building block for the development of new drugs with specific therapeutic applications.
Used in Diabetes Treatment:
In the field of diabetes treatment, 2,6-Dichloropyridine-4-boronic acid is used as a starting material for the preparation of orally bioavailable GPR40 agonists bearing a thiophenylpropanoic acid scaffold. GPR40 is a receptor that plays a role in glucose homeostasis, and its agonists have been shown to improve insulin secretion and glucose tolerance in diabetic patients. By incorporating 2,6-Dichloropyridine-4-boronic acid into the molecular structure of these agonists, researchers can develop more effective and safer treatments for diabetes.
Check Digit Verification of cas no
The CAS Registry Mumber 1072951-54-2 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,7,2,9,5 and 1 respectively; the second part has 2 digits, 5 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 1072951-54:
(9*1)+(8*0)+(7*7)+(6*2)+(5*9)+(4*5)+(3*1)+(2*5)+(1*4)=152
152 % 10 = 2
So 1072951-54-2 is a valid CAS Registry Number.
1072951-54-2Relevant articles and documents
SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS
-
Paragraph 0773; 0774, (2015/04/28)
The invention is concerned with the compounds of formula I or II: and salts thereof. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula I or II as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.
